Schering-Plough's Intron A
Executive Summary
Firm announced that its alpha-2 interferon has been approved in Canada for the treatment of hairy cell leukemia. The product is currently marketed for hairy cell leukemia in several countries including the U.K., Ireland, Columbia, the Philippines, Belgium, and Luxembourg. NDAs are pending in the U.S. for hairy cell leukemia, multiple myeloma, Kaposi's sarcoma, malignant melanoma, and prophylaxis of the common cold.